Key result
Female sex was associated with a lower 1-year risk of all-cause mortality (HR 0.80; 95% CI 0.68-0.94) compared with males after MitraClip repair, with no difference in the primary composite outcome.
Why the study?
Women have higher rates of adverse events after mitral valve surgery, prompting evaluation of whether outcomes after transcatheter edge-to-edge repair show similar sex-based trends.
Does female sex affect 1-year major adverse events in patients undergoing transcatheter edge-to-edge repair for mitral regurgitation?
Cohort
Yes
Does female sex affect 1-year major adverse events in patients undergoing transcatheter edge-to-edge repair for mitral regurgitation?
In patients undergoing transcatheter edge-to-edge repair for mitral regurgitation, females had similar 1-year composite adverse events but lower 1-year all-cause mortality compared to males, despite lower initial device success.
Answers are grounded in this paper and cite their sources.
Female sex linked to lower post-MitraClip mortality in observational data; leaves open causal effects on TEER outcomes.
BACKGROUND: Women have a higher rate of adverse events after mitral valve surgery. We sought to evaluate whether outcomes after transcatheter edge-to-edge repair intervention by sex have similar trends to mitral valve surgery. METHODS: The primary outcome was 1-year major adverse events defined as a composite of all-cause mortality, stroke, and any bleeding in the overall study cohort. Patients who underwent transcatheter edge-to-edge repair for mitral regurgitation with the MitraClip system in the Society of Thoracic Surgery/American College of Cardiology Transcatheter Valve Therapy registry were evaluated. Linked administrative claims from the Centers for Medicare and Medicaid Services were used to evaluate 1-year clinical outcomes. Associations between sex and outcomes were evaluated using a multivariable logistic regression model for in-hospital outcomes and Cox model for 1-year outcomes. At 1-year follow-up, the primary outcome did not differ by sex. Female sex was associated with lower adjusted 1-year risk of all-cause mortality (adjusted hazard ratio, 0.80 [CI, 0.68-0.94]), but the adjusted 1-year risk of stroke and any bleeding did not differ by sex. CONCLUSIONS: No difference in composite outcome of all-cause mortality, stroke, and any bleeding was observed between females and males. Adjusted 1-year all-cause mortality was lower in females compared with males.
No takes yet. Share an insight, caveat, or question.
Villablanca et al. (2021) conducted a cohort in Mitral regurgitation. Female sex vs. Male sex was evaluated on 1-year major adverse events defined as a composite of all-cause mortality, stroke, and any bleeding. Female sex was associated with a lower 1-year risk of all-cause mortality (HR 0.80; 95% CI 0.68-0.94) compared with males after MitraClip repair, with no difference in the primary composite outcome.
Synapse has enriched 10 related papers. Consider them for comparative context: